1
|
Mafi S, Rogez S, Darreye J, Alain S, Hantz S. Performance of the SureScreen Diagnostics COVID-19 antibody rapid test in comparison with three automated immunoassays. Diagn Microbiol Infect Dis 2023; 105:115900. [PMID: 36716586 PMCID: PMC9829606 DOI: 10.1016/j.diagmicrobio.2023.115900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Revised: 01/03/2023] [Accepted: 01/05/2023] [Indexed: 01/11/2023]
Abstract
Lateral flow immunoassays (LFIA) for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies are used for population surveillance and potentially individual risk assessment. The performance of the SureScreen Diagnostics LFIA targeting the spike protein was evaluated in comparison with 3 automated assays (Abbott Alinity-i SARS-CoV-2 IgG, DiaSorin Liaison® SARS-CoV-2 S1/S2 IgG, Wantai SARS-CoV-2 Ab ELISA). We assessed sensitivity using 110 serum samples from PCR confirmed COVID-19 infected patients. Specificity was evaluated using 120 prepandemic samples, including potential cross-reactive antibodies samples. Sensitivity ranged between 93.3% and 98.7% on samples collected >14 days postsymptom onset. All assays achieved a specificity >98%. Moreover, its performance seems not to be affected by Alpha, Beta or Delta variants over a wide range of antibody titers. The latter showed a very good agreement with the Wantai and the Abbott assays and a substantial agreement with the DiaSorin assay. Our data demonstrate the good clinical performance of the SureScreen Diagnostics LFIA for SARS-CoV-2 seroprevalence screening.
Collapse
Affiliation(s)
- Sarah Mafi
- Laboratoire de Bactériologie-Virologie-Hygiène, CHU Limoges, Limoges, France; INSERM, RESINFIT, U1092, Limoges, France.
| | - Sylvie Rogez
- Laboratoire de Bactériologie-Virologie-Hygiène, CHU Limoges, Limoges, France
| | - Jérôme Darreye
- Laboratoire de Bactériologie-Virologie-Hygiène, CHU Limoges, Limoges, France
| | - Sophie Alain
- Laboratoire de Bactériologie-Virologie-Hygiène, CHU Limoges, Limoges, France; INSERM, RESINFIT, U1092, Limoges, France
| | - Sébastien Hantz
- Laboratoire de Bactériologie-Virologie-Hygiène, CHU Limoges, Limoges, France; INSERM, RESINFIT, U1092, Limoges, France.
| |
Collapse
|
2
|
Nandakumar V, Profaizer T, Lozier BK, Elgort MG, Rychert J, Slev PR, Delgado JC. Evaluation of a Novel Multiplex Platform for Simultaneous Detection of IgG Antibodies Against the 4 Main SARS-CoV-2 Antigens. J Appl Lab Med 2022; 7:698-710. [PMID: 34741514 PMCID: PMC8767881 DOI: 10.1093/jalm/jfab161] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Accepted: 09/14/2021] [Indexed: 11/13/2022]
Abstract
BACKGROUND Numerous serology assays are available for detection of SARS-CoV-2 antibodies but are limited in that only 1 or 2 target antigen(s) can be tested at a time. Here, we describe a novel multiplex assay that simultaneously detects and quantifies IgG antibodies to SARS-CoV-2 antigens, spike (S), nucleocapsid (N), receptor-binding domain (RBD), and N-terminal domain (NTD) in a single well. METHODS Sensitivity was determined using samples (n = 124) from confirmed SARS-CoV-2 RT-PCR positive individuals. Prepandemic (n = 100) and non-COVID respiratory infection positive samples (n = 100) were used to evaluate specificity. Samples were analyzed using COVID-19 IgG multiplex serology assay from Meso Scale Discovery (MSD) and using commercial platforms from Abbott, EUROIMMUN, and Siemens. RESULTS At >14 days post-PCR, MSD assay displayed >98.0% sensitivity [S 100% (95% CI 98.0%-100.0%); N 98.0% (95% CI 97.2%-98.9%); RBD 94.1% (95% CI 92.6%-95.6%); NTD 98.0% (95% CI, 97.2%-98.9%)] and 99% specificity (95% CI 99.3%-99.7%) for antibodies to all 4 antigens. Parallel assessment of antibodies to more than 1 antigen improved the sensitivity to 100% (95% CI 98.0%-100.0%) while maintaining 98% (95% CI 97.6%-98.4%) specificity regardless of the combinations used. When AU/mL concentrations of IgG antibodies from the MSD assay were compared against the corresponding IgG signals acquired from the single target commercial assays, the following correlations were observed: Abbott (vs MSD N, R2 = 0.73), Siemens (vs MSD RBD, R2 = 0.92), and EUROIMMUN (vs MSD S, R2 = 0.82). CONCLUSION MSD assay offers an accurate and a comprehensive assessment of SARS-CoV-2 antibodies with higher sensitivity and equivalent specificity compared to the commercial IgG serology assays.
Collapse
Affiliation(s)
- Vijayalakshmi Nandakumar
- ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA
- Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Tracie Profaizer
- ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA
| | - Bucky K Lozier
- ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA
| | - Marc G Elgort
- ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA
- Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Jenna Rychert
- ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA
- Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Patricia R Slev
- ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA
- Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Julio C Delgado
- ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA
- Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA
| |
Collapse
|
3
|
Zhou K, Raoul JL, Blanc-Lapierre A, Seegers V, Boisdron-Celle M, Bourdon M, Mahammedi H, Lambert A, Moreau-Bachelard C, Campone M, Conroy T, Penault-Llorca F, Bellanger MM, Bigot F. COVID-19 Infections in Cancer Patients Were Frequently Asymptomatic: Description From a French Prospective Multicenter Cohort (PAPESCO-19). Clin Med Insights Oncol 2022; 16:11795549221090187. [PMID: 35465469 PMCID: PMC9021575 DOI: 10.1177/11795549221090187] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Accepted: 03/08/2022] [Indexed: 12/15/2022] Open
Abstract
Background Cancer patients (CPs) are considered more vulnerable and as a high mortality group regarding COVID-19. In this analysis, we aimed to describe asymptomatic COVID (+) CPs and associated factors. Methods We conducted a prospective study in CPs and health care workers (HCWs) in 4 French cancer centers (PAPESCO [PAtients et PErsonnels de Santé des Centres de Lutte Contre le Cancer pendant l'épidémie de COvid-19] study). This analysis used data recorded between June 17, 2020 and November 30, 2020 in CPs (first 2 waves, no variants). At inclusion and quarterly, CPs reported the presence of predefined COVID-19 symptoms and had a blood rapid diagnostic test; a reverse transcription polymerase chain reaction (RT-PCR) was done in case of suspected infection. Results A total 878 CPs were included; COVID-19 prevalence was similar in both CPs (8%) and HCWs (9.5%); of the 70 CPs (8%) who were COVID (+), 29 (41.4%) were and remained asymptomatic; 241/808 of the COVID (-) (29.8%) were symptomatic. 18 COVID (+) were hospitalized (2% of CPs), 1 in intensive care unit (ICU) and 1 died (0.1% of CPs and 2.4% of symptomatic COVID [+] CPs). Only the inclusion center was associated with clinical presentation (in Nancy, Angers, Nantes, and Clermont-Ferrand: 65.4%, 35%, 28.6%, and 10% CPs were asymptomatic, respectively). Conclusions Seroprevalence of COVID-19 in CPs was similar to that observed in HCWs; mortality related to COVID-19 among CPs was 0.1%. More than 40% of COVID (+) CPs were asymptomatic and one third of COVID (-) CPs had symptoms. Only geographic origin was associated with the presence or absence of symptoms. Social distancing and protective measures must be applied in CPs at home and when hospitalized.
Collapse
Affiliation(s)
- Ke Zhou
- Department of Human and Social Sciences, Institut de Cancérologie de l'Ouest (ICO), Saint-Herblain, France.,Department of Social Sciences, EHESP School of Public Health, Rennes, France
| | - Jean-Luc Raoul
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France
| | - Audrey Blanc-Lapierre
- Department of Biostatistic, Institut de Cancérologie de l'Ouest, Saint-Herblain, France
| | - Valérie Seegers
- Department of Biostatistic, Institut de Cancérologie de l'Ouest, Saint-Herblain, France
| | | | - Marianne Bourdon
- Department of Human and Social Sciences, Institut de Cancérologie de l'Ouest (ICO), Saint-Herblain, France.,UMR, INSERM 1246 SPHERE, Nantes and Tours University, Nantes, France
| | - Hakim Mahammedi
- Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France
| | - Aurélien Lambert
- Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France
| | | | - Mario Campone
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France
| | - Thierry Conroy
- Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France
| | | | - Martine M Bellanger
- Department of Human and Social Sciences, Institut de Cancérologie de l'Ouest (ICO), Saint-Herblain, France.,Department of Social Sciences, EHESP School of Public Health, Rennes, France
| | - Frédéric Bigot
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers, France
| |
Collapse
|
4
|
Zhou K, Blanc-Lapierre A, Seegers V, Boisdron-Celle M, Bigot F, Bourdon M, Mahammedi H, Lambert A, Campone M, Conroy T, Penault-Llorca F, Bellanger MM, Raoul JL. Anosmia but Not Ageusia as a COVID-19-Related Symptom among Cancer Patients-First Results from the PAPESCO-19 Cohort Study. Cancers (Basel) 2021; 13:3389. [PMID: 34298605 PMCID: PMC8303411 DOI: 10.3390/cancers13143389] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Revised: 06/28/2021] [Accepted: 06/29/2021] [Indexed: 12/30/2022] Open
Abstract
Background: Cancer patients may fail to distinguish COVID-19 symptoms such as anosmia, dysgeusia/ageusia, anorexia, headache, and fatigue, which are frequent after cancer treatments. We aimed to identify symptoms associated with COVID-19 and to assess the strength of their association in cancer and cancer-free populations. Methods: The multicenter cohort study PAPESCO-19 included 878 cancer patients and 940 healthcare workers (HCWs). At baseline and quarterly thereafter, they reported the presence or absence of 13 COVID-19 symptoms observed over 3 months and the results of routine screening RT-PCR, and they were systematically tested for SARS-CoV-2-specific antibodies. We identified the symptom combinations significantly associated with COVID-19. Results: Eight percent of cancer patients were COVID-19 positive, and 32% were symptomatic. Among the HCWs, these proportions were 9.5 and 52%, respectively. Anosmia, anorexia, fever, headache, and rhinorrhea together accurately discriminated (c-statistic = 0.7027) COVID-19 cases from cancer patients. Anosmia, dysgeusia/ageusia, muscle pain, intense fatigue, headache, and chest pain better discriminated (c-statistic = 0.8830) COVID-19 cases among the HCWs. Anosmia had the strongest association in both the cancer patients (OR = 7.48, 95% CI: 2.96-18.89) and HCWs (OR = 5.71, 95% CI: 2.21-14.75). Conclusions: COVID-19 symptoms and their diagnostic performance differ in the cancer patients and HCWs. Anosmia is associated with COVID-19 in cancer patients, while dysgeusia/ageusia is not. Cancer patients deserve tailored preventive measures due to their particular COVID-19 symptom pattern.
Collapse
Affiliation(s)
- Ke Zhou
- Department of Human and Social Sciences, Institut de Cancérologie de l’Ouest (ICO), 44805 Saint-Herblain, France; (M.B.); (M.M.B.)
| | - Audrey Blanc-Lapierre
- Department of Biostatistic, Institut de Cancérologie de l’Ouest, 44805 Saint-Herblain, France; (A.B.-L.); (V.S.)
| | - Valérie Seegers
- Department of Biostatistic, Institut de Cancérologie de l’Ouest, 44805 Saint-Herblain, France; (A.B.-L.); (V.S.)
| | | | - Frédéric Bigot
- Department of Medical Oncology, Institut de Cancérologie de l’Ouest, 49055 Angers, France;
| | - Marianne Bourdon
- Department of Human and Social Sciences, Institut de Cancérologie de l’Ouest (ICO), 44805 Saint-Herblain, France; (M.B.); (M.M.B.)
- Research Unit UMR INSERM 1246 SPHERE, Universités de Nantes et Tours, 44035 Nantes, France
| | - Hakim Mahammedi
- Department of Medical Oncology, Centre Jean Perrin, 63011 Clermont-Ferrand, France;
| | - Aurélien Lambert
- Department of Medical Oncology, Institut de Cancérologie de Lorraine, 54511 Vandoeuvre-lès-Nancy, France; (A.L.); (T.C.)
| | - Mario Campone
- Department of Medical Oncology, Institut de Cancérologie de l’Ouest, 44805 Saint-Herblain, France; (M.C.); (J.-L.R.)
| | - Thierry Conroy
- Department of Medical Oncology, Institut de Cancérologie de Lorraine, 54511 Vandoeuvre-lès-Nancy, France; (A.L.); (T.C.)
| | | | - Martine M. Bellanger
- Department of Human and Social Sciences, Institut de Cancérologie de l’Ouest (ICO), 44805 Saint-Herblain, France; (M.B.); (M.M.B.)
- Department of Social Sciences, EHESP School of Public Health, 35043 Rennes, France
| | - Jean-Luc Raoul
- Department of Medical Oncology, Institut de Cancérologie de l’Ouest, 44805 Saint-Herblain, France; (M.C.); (J.-L.R.)
| |
Collapse
|
5
|
Filardo S, Di Pietro M, Diaco F, Romano S, Sessa R. Oxidative Stress and Inflammation in SARS-CoV-2- and Chlamydia pneumoniae-Associated Cardiovascular Diseases. Biomedicines 2021; 9:biomedicines9070723. [PMID: 34202515 PMCID: PMC8301438 DOI: 10.3390/biomedicines9070723] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 06/18/2021] [Accepted: 06/22/2021] [Indexed: 12/13/2022] Open
Abstract
Throughout the years, a growing number of studies have provided evidence that oxidative stress and inflammation may be involved in the pathogenesis of infectious agent-related cardiovascular diseases. Amongst the numerous respiratory pathogens, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus responsible for the global ongoing pandemic, and Chlamydia pneumoniae, a widely known intracellular obligate bacteria, seem to have an essential role in promoting reactive oxygen species and cytokine production. The present review highlights the common oxidative and inflammatory molecular pathways underlying the cardiovascular diseases associated with SARS-CoV-2 or C. pneumoniae infections. The main therapeutic and preventive approaches using natural antioxidant compounds will be also discussed.
Collapse
Affiliation(s)
- Simone Filardo
- Department of Public Health and Infectious Diseases, University of Rome “Sapienza”, P.le Aldo Moro, 5, 00185 Rome, Italy; (M.D.P.); (F.D.); (R.S.)
- Correspondence:
| | - Marisa Di Pietro
- Department of Public Health and Infectious Diseases, University of Rome “Sapienza”, P.le Aldo Moro, 5, 00185 Rome, Italy; (M.D.P.); (F.D.); (R.S.)
| | - Fabiana Diaco
- Department of Public Health and Infectious Diseases, University of Rome “Sapienza”, P.le Aldo Moro, 5, 00185 Rome, Italy; (M.D.P.); (F.D.); (R.S.)
| | - Silvio Romano
- Cardiology, Department of Life, Health and Environmental Sciences, University of L’Aquila, P.le Salvatore Tommasi, 1, 67100 L’Aquila, Italy;
| | - Rosa Sessa
- Department of Public Health and Infectious Diseases, University of Rome “Sapienza”, P.le Aldo Moro, 5, 00185 Rome, Italy; (M.D.P.); (F.D.); (R.S.)
| |
Collapse
|